- Hello Jeff - A special thanks to PEP, Pat, for providing
this information on my message board.
-
- Patricia Doyle
-
- Certain Flu-Like Diseases To
Be Quarantined Under New Bush Executive Order
-
- I hope the date of this order is not significant. Just
don't get into any white boxcars - especially the ones without windows...
--Pat
-
- For Immediate Release
- Office of the Press Secretary
- April 1, 2005
-
- Executive Order: Amendment to E.O. 13295
Relating to Certain Influenza Viruses and Quarantinable Communicable Diseases
-
- By the authority vested in me as President by the Constitution
and the laws of the United States of America, including section 361(b)
of the Public Health Service Act (42 U.S.C. 264(b)), it is hereby ordered
as follows:
-
- Section 1. Based upon the recommendation of the Secretary
of Health and Human Services, in consultation with the Surgeon General,
and for the purpose set forth in section 1 of Executive Order 13295 of
April 4, 2003, section 1 of such order is amended by adding at the end
thereof the following new subsection:
-
- "(c) Influenza caused by novel or re-emergent influenza
viruses that are causing, or have the potential to cause, a pandemic.".
-
- Sec. 2. This order is not intended to, and does not,
create any right or benefit, substantive or procedural, enforceable at
law or in equity by any party against the United States, its departments,
agencies, entities, officers, employees or agents, or any other person.
-
- GEORGE W. BUSH
- THE WHITE HOUSE,
-
- April 1, 2005.
- http://www.whitehouse.gov
-
- Post Extras:
- PEB
- addict
-
- Reged: 04/11/03
- Posts: 671
- Loc: England
- Contract awarded to Develop Influenza Vaccines
- #2820 - 04/04/05 08:15 AM (81.86.164.202)
-
- How very convenient - at the same time as the order to
quarantine, a contract is awarded to develop vaccines. Using cell based
method - which definitely relies on none of the experiments escaping accidentally!
But we feel safe with that - don't we.......... Pat
-
- News Release
- FOR IMMEDIATE RELEASE
- Friday, April 1, 2005
- HHS Press Office
- (202) 690-6343
- http://www.hhs.gov
-
- HHS Awards $97 Million Contract to Develop Cell Culture-Based
Influenza Vaccine Effort Designed to Diversify and Accelerate Vaccine Production
to Enhance Pandemic Preparedness
-
- HHS Secretary Mike Leavitt announced today that the Department
has awarded a $97 million contract to Sanofi Pasteur to speed the production
process for new influenza vaccines for the U.S. The five-year award supports
the development of advanced techniques using a cell-based, rather than
an egg-based, approach to producing influenza vaccines. The contract also
calls for plans to establish a U.S.-based, cell cultured influenza vaccine
manufacturing facility.
-
- "This action begins the process of speeding up influenza
vaccine production, improving surge capacity and scaling up U.S. manufacturing
capability," Secretary Leavitt said. "As a result, this should
allow the U.S. to have influenza vaccines in a more timely, less laborious
manner, and it provides another tool for responding to and controlling
a global influenza pandemic."
-
- Currently licensed influenza vaccines are produced in
chicken eggs in a process that takes nearly nine months. Scientists must
first select the virus strains that they anticipate will be the predominant
strains circulating in the U.S. during the following season. These strains
are then adapted to grow in eggs. Manufacturers inject each adapted virus
strain separately into millions of fertilized eggs, which are subsequently
incubated to produce influenza virus. Large batches of these eggs are harvested
and blended into a single vaccine product that includes all three influenza
virus strains.
-
- Using a cell culture approach to producing influenza
vaccine offers a number of benefits. Vaccine manufacturers can bypass the
step needed to adapt the virus strains to grow in eggs. In addition, cell
culture-based influenza vaccines will help meet surge capacity needs in
the event of a shortage or pandemic, since cells may be frozen in advance
and large volumes grown quickly. U.S. licensure and manufacture of influenza
vaccines produced in cell culture also will provide security against risks
associated with egg-based production, such as the potential for egg supplies
to be contaminated by various poultry-based diseases. Finally, the new
cell-based influenza vaccines will provide an option for people who are
allergic to eggs and therefore unable to receive the currently licensed
vaccines.
-
- Cell-based influenza vaccines use mammalian cells to
grow the influenza viruses used in the vaccine. Under this contract, Sanofi
Pasteur, a part of the Sanofi Pasteur Group, will develop, scale-up, and
manufacture clinical investigational lots of inactivated influenza vaccines
using human cells. These vaccines will be tested in human clinical trials
in adult, elderly, and pediatric populations within the U.S. In addition,
Sanofi Pasteur will develop plans for a U.S. manufacturing facility capable
of producing at least 300 million doses of a pandemic influenza vaccine
using this technology.
-
- This contract is one of several contracts that HHS has
awarded during the past year to enhance pandemic influenza preparedness
and the annual influenza vaccine supply. Earlier awards were made to increase
domestic influenza vaccine capacity, secure year round vaccine raw materials
and supplies, and develop pandemic-like vaccine candidates for clinical
evaluation.
-
- This contract follows the August 2004 release of the
draft National Pandemic Influenza Preparedness and Response Plan, which
outlines a coordinated national strategy to prepare for and respond to
an influenza pandemic. The draft plan may be found online at http://www.hhs.gov/nvpo/pandemicplan
and is a result of years of work by the Department.
-
- Note: All HHS press releases, fact sheets and other press
materials are available at
- http://www.hhs.gov/news.
- Last revised: April 1, 2005
-
- The White House | FirstGov
- U.S. Department of Health & Human Services ·
200
- Independence Avenue, S.W. · Washington, D.C.
- 20201
-
- Patricia A. Doyle, PhD
- Please visit my "Emerging Diseases" message
- board.
-
- Zhan le Devlesa tai sastimasa
- Go with God and in Good Health
|
